Caila B Vaughn
Overview
Explore the profile of Caila B Vaughn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
245
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nair N, Vaughn C, Ochs-Balcom H, Nie J, Trevisan M, Freudenheim J
Cancer Causes Control
. 2023 Aug;
35(1):103-109.
PMID: 37594683
Purpose: There is increasing evidence that sleep duration may affect breast cancer survival through effects on circadian function, influencing disease progression. However, further investigation of this association is needed. Methods:...
2.
Vaughn C, Kavak K, Jakimovski D, Qutab N, Avila R, Vignos M, et al.
Neurodegener Dis Manag
. 2023 Feb;
13(3):151-159.
PMID: 36779318
Patient-reported outcomes (PROs) are valuable measures for routine clinical care of people with multiple sclerosis (pwMS). 646 pwMS treated with interferon-β-1a (IFN-β-1a) were retrospectively included from the New York State...
3.
Fuchs T, Vaughn C, Benedict R, Weinstock-Guttman B, Bergsland N, Jakimovski D, et al.
Brain Imaging Behav
. 2022 Jan;
16(3):1252-1259.
PMID: 34985619
Background: Overall burden of white matter damage is associated with increased self-report fatigue severity in people with multiple sclerosis. However, a paradoxically opposite association was reported for white matter damage...
4.
Jakimovski D, Kavak K, Vaughn C, Goodman A, Coyle P, Krupp L, et al.
Mult Scler Relat Disord
. 2021 Dec;
57:103406.
PMID: 34915316
Background: Multiple sclerosis (MS) patients with stable disease course might view continued treatment as unnecessary. However, guidelines regarding treatment discontinuation are currently lacking. Objective: To assess the clinical course after...
5.
Jakimovski D, Zivadinov R, Vaughn C, Ozel O, Weinstock-Guttman B
J Neurol Sci
. 2021 Jun;
427:117552.
PMID: 34175775
Background: Neurodegenerative changes in multiple sclerosis (MS) are associated with long-term disability progression (DP). Optical coherence tomography (OCT) measures may be used to monitor DP. Objective: To determine significant effects...
6.
Mowla A, Sharifian-Dorche M, Mehla S, Lail N, Sharifian-Dorche A, Vaughn C, et al.
J Neurol Sci
. 2021 Apr;
425:117451.
PMID: 33882341
Aim: To study the effects of pretreatment with Antiplatelet (AP) before IV thrombolysis (IVT) on the rate of symptomatic intracranial hemorrhage (sICH) and functional outcome in patients with Acute Ischemic...
7.
Mowla A, Memon A, Razavi S, Lail N, Vaughn C, Mohammadi P, et al.
J Stroke Cerebrovasc Dis
. 2021 Feb;
30(5):105678.
PMID: 33640783
Introduction: Current guidelines allow the administration of intravenous recombinant tissue plasminogen activator (IV r-tPA) to warfarin-treated patients with acute ischemic stroke (AIS) who have an international normalized ratio (INR) of...
8.
Zambrano Espinoza M, Lail N, Vaughn C, Shirani P, Sawyer R, Mowla A
Cerebrovasc Dis
. 2021 Jan;
50(2):141-146.
PMID: 33423033
Background: We sought to investigate the effect of obesity and BMI on functional outcome and rate of symptomatic intracranial hemorrhage (sICH) in a large sample of patients with acute ischemic...
9.
Mowla A, Shah H, Lail N, Vaughn C, Shirani P, Sawyer R
Cerebrovasc Dis
. 2020 Sep;
49(5):503-508.
PMID: 32927457
Aim: The aim of this was to study the effects of statins and their intensity on symptomatic intracranial hemorrhage (sICH) and outcome after IV thrombolysis (IVT) for acute ischemic stroke...
10.
Jakimovski D, Vaughn C, Eckert S, Zivadinov R, Weinstock-Guttman B
Expert Opin Drug Saf
. 2020 Aug;
19(9):1121-1142.
PMID: 32744073
Introduction: The portfolio of multiple sclerosis (MS) disease modifying treatments (DMTs) has significantly expanded over the past two decades. Given the lifelong use of MS pharmacotherapy, understanding their long-term safety...